DAIICHI SANKYO, INC.

Daiichi Sankyo and MSD report Phase III HERTHENA-Lung02 trial of patritumab deruxtecan met primary endpoint of progression-free survival in EGFR-mutated NSCLC patients. The trial showed a significant PFS improvement for patritumab deruxtecan versus chemotherapy, with a safety profile consistent with previous studies.

Merck and Daiichi Sankyo's patritumab deruxtecan met primary endpoint in Phase III HERTHENA-Lung02 study for EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival. Safety profile consistent with prior studies, though two grade 5 interstitial lung disease deaths occurred. Full results to be presented at a medical meeting.

Patritumab deruxtecan showed significant PFS improvement in HERTHENA-Lung02 trial for EGFR-mutated NSCLC patients previously treated with EGFR TKI, compared to platinum plus pemetrexed chemotherapy.

PD-1 inhibition with pembrolizumab before and after surgery significantly improves 5-year overall survival (86.6% vs 81.7%) in high-risk early triple-negative breast cancer, according to KEYNOTE-522 trial results.

Enhertu (trastuzumab deruxtecan) demonstrated significant overall and intracranial clinical activity, including prolonged PFS, in HER2-positive mBC patients with brain metastases in the DESTINY-Breast12 trial. The findings support Enhertu's potential as a second-line treatment, with a 12-month PFS rate of 61.6% and CNS PFS rate of 58.9% among patients with brain metastases.

Daiichi Sankyo and Merck's patritumab deruxtecan shows significant PFS improvement in EGFR-mutated NSCLC post-EGFR TKI treatment, prompting discussions with global regulatory authorities.

Daiichi Sankyo and Merck's antibody-drug conjugate, patritumab deruxtecan, met Phase 3 trial goals, delaying EGFR-mutated non-small cell lung cancer progression better than chemotherapy. The drug uses an antibody to target tumor cells and release a toxic chemical. Daiichi has six ADCs using deruxtecan chemotherapy, including Enhertu, with sales of $1.8 billion in H1 2024. Merck's $22 billion deal with Daiichi aims to bolster its pipeline as Keytruda patents near expiration.

HIMALAYA trial results show AstraZeneca’s Imfinzi plus Imjudo reduced HCC death risk by 24% at 5 years, with 19.6% survival vs 9.4% with sorafenib.

The STRIDE regimen's safety profile aligns with known medicine profiles, with no new safety signals. IMFINZI and IMJUDO are approved for advanced or unresectable HCC in multiple countries. Immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, and endocrinopathies, are noted, necessitating close monitoring and prompt management. Infusion-related reactions and complications post-HSCT are also highlighted. IMFINZI and IMJUDO are not recommended for pregnant or breastfeeding women.

Daiichi Sankyo reports positive Phase I trial results for DS-9606, an ADC targeting CLDN6 in advanced solid tumours, showing promising safety, tolerability, and clinical activity.